Le Lézard
Classified in: Health

ZAP Surgical Announces First Facility on the East Coast Initiates Patient Treatment Using New Non-Invasive Brain Tumor Therapy


SAN CARLOS, Calif., Sept. 22, 2020 /PRNewswire-PRWeb/ -- ZAP Surgical Systems, Inc. today announced ZAP-X® Gyroscopic Radiosurgery® patient treatments have commenced at MedStar Georgetown Cancer Institute at MedStar Southern Maryland Hospital Center in Clinton, MD.

For many primary and metastatic brain tumors, stereotactic radiosurgery (SRS) has proven to be an effective treatment with outcomes equivalent to invasive surgical procedures. Unlike surgery however, SRS is a non-invasive outpatient procedure with no surgical incision and often requires little to no patient recovery period.

"Radiosurgery is among the most important innovations in modern medicine for the treatment of many brain tumors," said Dr. Adler, CEO of ZAP Surgical Systems, and professor emeritus of neurosurgery and radiation oncology at Stanford University. "With ZAP-X, patients can be treated without the potential complications and recovery of a surgical procedure."

The new ZAP-X technology is recognized for using gyroscopic motion to direct radiosurgical beams from hundreds of unique angles to precisely concentrate radiation to the tumor target. With this unique approach, radiation doses rapidly dissipate beyond the tumor to mitigate potential toxicities to adjacent healthy brain tissue.

ZAP-X is also the first and only dedicated radiosurgery system which does not require live radioactive sources, thus significantly reducing hospital costs while also eliminating heightened security requirements.

"MedStar Health is long renowned for offering world-class cancer care," added Dr. Adler, "We are honored to partner with their clinical team to bring this potentially life-saving therapy to southern Maryland and the surrounding area."

For more about the ZAP-X Gyroscopic Radiosurgery platform, please visit: https://zapsurgical.com/. Detailed system overview animations can be found at https://youtu.be/9ph-cdb5QO0.

About ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgerytm platform. ZAP was founded in 2014 by John R. Adler, MD, professor emeritus of neurosurgery and radiation oncology at Stanford University, and CEO of ZAP Surgical Systems. Dr. Adler is also the inventor of the CyberKnife® and founder of Accuray, Inc. FDA-cleared in September 2017, ZAP-X utilizes a modern linear accelerator to eliminate the historical use of Cobalt-60 and the related costs and challenges of handling live radioactive isotopes. ZAP-X also incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. Learn more at http://www.zapsurgical.com.

Contact:
Mark Arnold
Senior Vice President, Marketing
ZAP Surgical Systems, Inc.
Email: [email protected]

 

SOURCE ZAP Surgical


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: